Ozempic Face and Body: What’s Happening to Your Skin and What Actually Helps

If you’ve lost significant weight on a GLP-1 medication, you may have noticed something the scale doesn’t show: your face looks more hollow, older, or tired than the number on it would suggest, and skin on your body may feel looser than it used to. This isn’t in your head, and it isn’t really about “aging faster.” It’s a predictable, well-understood side effect of rapid fat loss, and it’s one Dr. Jane Yoo treats regularly at her Midtown Manhattan practice.

This page explains what’s actually happening to your skin on GLP-1 medications, and walks through the treatment paths, both for the face and for the body, that address it.

What Is “Ozempic Face” (and “Ozempic Body”)?

“Ozempic face” and “Ozempic body” are shorthand terms, not official medical diagnoses, for the facial volume loss and skin laxity that can follow rapid, significant weight loss on GLP-1 receptor agonist medications.

Which GLP-1s Are Involved

The term “Ozempic face” gets used as shorthand for the whole drug class, but the same effects can follow any GLP-1 medication that produces meaningful, relatively fast fat loss — injectable or oral:

  • Semaglutide: Ozempic, Wegovy (injectable and the newer oral tablet), Rybelsus
  • Tirzepatide: Mounjaro, Zepbound
  • Liraglutide: Saxenda, Victoza
  • Dulaglutide: Trulicity
  • Newer oral options: orforglipron (brand name Foundayo), the first non-peptide oral GLP-1

Regardless of which formulation or brand, the aesthetic effects described on this page stem from the same underlying mechanism: significant fat loss happening faster than skin can typically adapt to.

Why Rapid Fat Loss Affects Skin Differently

Skin is elastic, but that elasticity has limits. When fat is lost gradually over years, skin generally has time to retract along with it. When a large amount of fat is lost in a matter of months, which is common across this drug class, skin often can’t keep pace. The result is a mismatch: less volume underneath, but skin that hasn’t fully adjusted to the new contour.

Two Different Problems, Two Different Fixes

It’s worth separating these clearly, because they’re treated differently.

Facial Volume Loss (Fat Pad Depletion)

The face has distinct fat pads that give it structure and a youthful contour, in the cheeks, temples, and under the eyes, among other areas. GLP-1 medications reduce fat throughout the body, including these facial pads. Losing that volume is what produces the hollowed, gaunt, or aged appearance people describe as “Ozempic face.”

Skin Laxity (Loss of Elasticity)

Separately, skin itself can lose its ability to snap back once the tissue beneath it shrinks, particularly with rapid or substantial weight loss, and particularly in patients over their mid-30s, when collagen and elastin production naturally begins to decline. This is the mechanism behind loose or crepey-feeling skin on the body: abdomen, arms, neck, and thighs are common areas.

Ozempic Face: Signs and Treatment

Facial volume loss shows up as hollowing in the cheeks and temples, more prominent nasolabial folds, and a generally more tired or aged look, even at a healthy, stable weight. Treatment centers on restoring what’s been lost: dermal filler for immediate structure, biostimulator injectables like Sculptra to rebuild volume gradually by stimulating the body’s own collagen, and RF and HIFU as standard components to tighten and support the skin, typically used in combination depending on the degree of volume loss.

Read the full guide to Ozempic Face treatment

Loose Skin on the Body: Signs and Treatment

Body skin laxity shows up as looseness or crepiness in the abdomen, upper arms, neck, or thighs, skin that doesn’t sit as firmly against the body as it did before weight loss. This is a structural skin problem rather than a volume problem, so treatment focuses on stimulating the skin’s own collagen production through non-surgical devices like RF and HIFU, along with biostimulator injectables like Sculptra in select areas, with surgical skin removal reserved for more significant excess skin that non-surgical options can’t meaningfully improve.

Read the full guide to loose skin treatment

Can You Prevent This While Losing Weight?

To some extent, losing weight more gradually, maintaining muscle mass through strength training, and supporting skin health throughout the process can all reduce how pronounced these changes are. But for patients losing substantial weight, some degree of volume loss or skin laxity is a realistic expectation rather than something that can be fully prevented.

Read the full breakdown: Does skin tighten after weight loss naturally?

Frequently Asked Questions

What is “Ozempic face”?

“Ozempic face” is a term for the facial volume loss and skin laxity that can appear after rapid weight loss on GLP-1 medications, whether injectable (Ozempic, Wegovy, Mounjaro, Zepbound, Saxenda) or oral (Rybelsus, the Wegovy pill, Foundayo). It happens because these medications reduce facial fat pads along with body fat, and skin doesn’t always retract at the same pace fat is lost.

Is Ozempic face permanent?

Not typically. The underlying volume loss and skin laxity are treatable, though they don’t usually reverse fully on their own. Dermatologic treatments such as dermal filler, biostimulator injectables like Sculptra, and RF/HIFU are commonly used to address it.

Do all GLP-1 medications cause this?

Any medication that produces significant, relatively rapid fat loss can produce these effects, whether it’s semaglutide, tirzepatide, liraglutide, or one of the newer oral options. The degree varies by how much weight is lost, how quickly, and individual factors like age and baseline skin elasticity.

What’s the difference between Ozempic face and normal aging?

Both involve some volume loss, but Ozempic face happens faster and more dramatically because it’s driven by rapid, significant fat reduction rather than gradual, age-related fat pad changes over years.

When to See a Dermatologist

If you’ve lost weight on a GLP-1 medication and are noticing facial hollowing, skin laxity, or both, a consultation can clarify which of these is driving what you’re seeing — and which treatments (or combination) actually fit your situation. Dr. Yoo evaluates both facial volume and skin quality at consultation to build a plan specific to what’s happening in your case, not a generic protocol.

Book a Consultation!

author avatar
Dr. Jane Yoo Board-Certified Dermatologist and Mohs Surgeon
Jane Yoo, MD, MPP, is a Korean American board-certified dermatologist and fellowship-trained Mohs surgeon based in Midtown Manhattan. She is a Clinical Assistant Professor at the Icahn School of Medicine at Mount Sinai and the founder of Jane Yoo MD, PLLC and the Clinical Research Center of New York. Dr. Yoo holds an undergraduate degree from MIT and a Masters of Public Policy from Harvard's Kennedy School of Government. She completed her Mohs micrographic surgery fellowship at Yale. Her clinical and research focus spans aesthetic clinical trials including injectables and laser technology, skincare formulation and sunscreen science, K-Beauty and skin of color, ultrasound guided filler dissolution, artificial intelligence and beauty tech. Dr. Yoo's research is indexed under ORCID 0000-0002-7112-8963.